CEO AGM Presentation August 2019
TRUSCREEN’S MISSION To provide primary screening for cervical cancer in developing nations via the TruScreen device – the latest single-visit, real time screening technology solution. TruScreen August 2019 CEO Presentation 2
FY19 PRIORITIES, RESULTS & BUSINESS HIGHLIGHTS At the Start of the year we set our key business priorities as Submit and Continue to be gain adoption assessed and Export low Enhance our Expand in selected endorsed by Increase sales technology distribution manufacturing international key opinion of TruScreen manufacturing networks capability government leaders and to key market screening government programmes policy setters TruScreen August 2019 CEO Presentation 3
FY19 PRIORITIES, RESULTS & BUSINESS HIGHLIGHTS FY19 Results and Highlights: - Pilot in-house manufacturing - Sales up 132% to NZ $1.9m facility established - Total Revenue up 43% to - Investigating overseas NZ$3.11m assembly/manufacturing - New Distribution agreements in - Successful Capital Raise Oct Russia, Zimbabwe, Saudi, Israel, 2018 Sri Lanka - New NED Con Hickey appointed - China Pilot Studies Aug 2018 - Continued work with aid - New Chairman Appointed Sept organisations in East Africa 2018 - WHO Recognition to increase - New Chief Financial Officer access to international programs Appointed Nov 2018 and funding organisations - Migrated from NZAX to NZX Main Board Dec 2018 TruScreen August 2019 CEO Presentation 4
CONTINUE ON OUR STRATEGY Building our internationally approved device, experiencing sales momentum in key markets through a global distribution model Drive Sales and Strategic Growth from Partnerships Geographic and Footprint Relationships Manufacturing Capabilities People and - Underpinned Capability by Research and 87% of deaths from cervical cancer occur in low and middle Development income nations There is limited lab infrastructure and diagnostic technicians TruScreen meets the market demand 5 TruScreen August 2019 CEO Presentation
THE OPPORTUNITY Screening age population - solution for cervical cancer screening needed RUSSIA 44M MIDDLE CHINA INDIA EAST 401M 302M 70M MEXICO 31M AFRICA LATIN 226M AMERICA 120M Ref: Based on U.S Central Intelligence Agency (CIA) World Factbook TruScreen August 2019 CEO Presentation 6
THE OPPORTUNITY TruScreen’s addressable market is NZD $166m Screening No. of Screen Fourth most Target Market Population Women Annually common cancer Share NZD $1M (x1M) (x 1M) (x 1M) worldwide China 401 8% 32.08 10.69 86.49 1BN+ women of Mexico 31 6% 1.86 0.62 6.38 screening age in Russia 44 6% 2.64 0.88 10.35 low and middle Africa 226 2% 4.52 1.51 22.16 income India 302 3% 9.06 3.02 31.09 Mid East 70 2% 1.40 0.47 5.49 countries Latam 120 1% 1.20 0.40 4.71 87% of deaths Total 1194 52.76 17.59 166.67 occur in low and middle income nations NZD : USD 0.68 7 TruScreen August 2019 CEO Presentation
COMMERCIAL STRATEGY MARKET ENTRY & TARGETING LOW/MIDDLE SUCCESS TO DATE DEVELOPMENT INCOME COUNTRIES Build Awareness Strong Sales Momentum • Lacking lab infrastructure • Key Opinion Leaders • Total Sales FY19 > 190 • High prevalence of HPV & engagement Devices cervical cancer • Social Media • Annuity revenue with SUS • Governments investing in • Medical conferences orders > 150,000 SUS units women’s health • Clinical trials/studies • Market need for portable Global Distribution Expand Distribution real time accurate screening • 31 countries • Local distributor strategy technology • Pilot public health initiatives • Public health initiatives • Partnerships with Non- Research and Development Government Organisations and • 2 nd generation device Government agencies Technology transfer to key markets TruScreen August 2019 CEO Presentation 8
SALES DATA - FY2019 Commercial stage cervical cancer screening technology • Key Focus is on China (400m women of screening age) • Use AIIMS report to open Govt sales in India • Continue to support current second tier markets – Russia, South East Asia and Vietnam, Mexico and Middle East • Continue to work with aid organisations in East Africa • Receiving recognition from key NGO’s: UNITAID, the World Health Organisation and Clinton Health Access Initiative COMMERCIALISED IN MULTIPLE MARKETS SALES FOCUS TruScreen August 2019 CEO Presentation 9
SALES DATA - FY2019 TruScreen (Units) SUS Growth ACCELERATING SALES GROWTH ACCELERATING SALES OF DISPOSABLE SUS TruScreen August 2019 CEO Presentation 10
KEY MARKET: CHINA FACTS Screening Programs • Various programs run by Central, State and Municipal governments, plus charities and major state owned enterprises (e.g. Sinopec) Market Presence • COGA (Chinese Obstetricians & Gynaecologists Association) – screen 20,000 women in public hospitals. Commenced Nov 2018, 52 Hospitals installed, completion in 2020 • Western China target 190 hospitals • Hospital target usage of SUS: 150/m, with some using 1,000/m World’s biggest Pipeline • KOL support from COGA cervical cancer market • CDC program: Target is adoption in 3,000 women and children’s hospitals (Screening age population: 400M) • COGA program: Target to Open up 200 public hospitals in 2019 • West China: Target 90 devices in 2019 and another 100 in 2020 for government screening 52% of TruScreen sales program - up to 2M women every two years • Target Installation in 50 ‘Breast and Cervical Cancer Centres’ in rural areas in 2019 Initial distribution agreement commencing with Xinjian province in the far west signed 2014 • ‘Medical Checkup’ centres - target at least 50 in 2019, and then expand TruScreen August 2019 CEO Presentation 11
KEY MARKET: LATIN AMERICA FACTS Screening Programs • Split between Central Govt and State Health Secretariats, public Insurance agencies (ISSTE and IMES), armed forces and state owned monopolies – e.g. Pemex • New central government is conducting an overhaul of the National Health administration and TruScreen will adjust its plans to suit Market Presence • Installed in National Cancer Institute • Installed in ‘Health Train’, ISSTE, Pemex and state -owned hospitals Mexico Pipeline • Central and State Government Health Secretariats 31M women of screening age • National health insurer, ISSSTE - 500,000 pap tests p.a. (installed in 4 ISSTE hospitals) 8% of TruScreen sales • National oil monopoly, PEMEX - 60,000 pap tests p.a. (installed in 2 Pemex hospitals) • Private lab and clinic chains Initial distribution agreement signed 2015 TruScreen August 2019 CEO Presentation 15
KEY MARKET: RUSSIA FACTS Screening Programs • No central government screening programs • State and municipal governments conduct ad hoc programs Market Presence • Distribution agreement with IMSystems with initial orders in Feb 2019 • Advanced payment of USD $250k for multiple TruScreen Devices and Single Use Sensors (SUS) • IMSystems has extensive expertise in the distribution of medical equipment and devices in Russia and partnerships with global brands and manufacturers, including GE Healthcare. 44M women of screening age Pipeline • Evaluated by ROSZDRAVNADZOR (Russia FDA) 20% of TruScreen sales • Major target is State Government Health Systems, starting with St Petersburg Original agreement in 2015 • Private clinics and hospitals New agreement distribution agreement signed in Feb 2019 TruScreen August 2019 CEO Presentation 13
KEY MARKET: INDIAN SUBCONTINENT Screening Programs FACTS • Split between Central Govt and State Health agencies and govt institutions – Armed Forces, State Rail et al. • Central government has mandated that all women over 25 be screened for breast and cervical cancer Market Presence • Engaged major distributor (KLAB) – 700 employees • Commenced marketing in three regions Central – Delhi NCR, Madhya Pradesh, Haryana, Telegana and Maharashtra North East - Manipur and Assam India South – Tamil Nadu 300M women of screening age Pipeline • All India Institute of Medical Science (AIIMS) • Central and state governments (aim for inclusion in the 2020 National Ministry of Health Initial distribution agreement signed 2017 Budget) • Armed Forces Hospitals and Armed Forces Medical Research Centre Sales commenced in FY18 • Major Private Hospital Groups (e.g Fortis, Apollo) • Tenders for State Screening Programs TruScreen August 2019 CEO Presentation 14
KEY MARKET: AFRICA FACTS Screening Programs • Step 1: National Aids Council (NAC) of Zimbabwe • Step 2: Use this for both government and NGO support for other projects in East Africa – Malawi and Mozambique submission being prepared • Collaborating with DYSIS Medical and WISAP Medical Technology GmbH Market Presence • TruScreen selected by Zimbabwe NAC program for more than 800,000 HIV-affected women • Ministry of Health supported aid grant application to use TruScreen for a national screening program 227M women of screening age Pipeline • Evaluated by National Aids Council of Zimbabwe 13.1M women suffer from HIV • Target East and Southern African countries with high HIV prevalence Zimbabwe 7% of TruScreen sales HIV+ women up to x5 increased risk of developing cervical cancer TruScreen August 2019 CEO Presentation 15
Recommend
More recommend
